Mohammed S. Abdel-Maksoud
Design, synthesis, and anticancer activity of imidazo[2,1-b]oxazole-based RAF kinase inhibitors
Abdel-Maksoud, Mohammed S.; Ammar, Usama M.; El-Gamal, Mohammed I.; Gamal El-Din, Mahmoud M.; Mersal, Karim I.; Ali, Eslam M.H.; Yoo, Kyung Ho; Lee, Kyung-Tae; Oh, Chang-Hyun
Authors
Dr Usama Ammar U.Ammar@napier.ac.uk
Lecturer
Mohammed I. El-Gamal
Mahmoud M. Gamal El-Din
Karim I. Mersal
Eslam M.H. Ali
Kyung Ho Yoo
Kyung-Tae Lee
Chang-Hyun Oh
Abstract
In the present work, a novel series of B-RAF kinase inhibitors having imidazo[2,1-b]oxazole scaffold was designed and synthesized based on the structures of the well-known B-RAF inhibitors. The twenty two final compounds were tested over A375 and SKMEL28 cell lines to determine the primary cytotoxic activity of these compounds, and their activities were compared with that of sorafenib as a standard. Compounds 11c, 11e, 11o, 11q, 11r, and 11u exhibited higher cellular activity compared to sorafenib with IC 50 values of 7.25, 8.03, 9.81, 8.47, 4.70, and 9.04 µM, respectively and 10.38 µM for sorafenib. In addition, the target compounds were screened for their anticancer activity by the NCI-60 cell line assay. Compounds 11v and 11u were the most active compounds with percent inhibition reached 95.99% for 11v and 87.03% for 11u over K562 cell line at 10 µM concentration. Compound 11v was selected for 5-dose test mode. Furthermore, the kinase inhibitory activities of 11a, 11c, 11e, 11i, 11o, 11q, 11r, 11u, and 11v were determined against wild-type B-RAF, V600E-B-RAF, and RAF1. Compound 11o was the most potent against V600E-B-RAF with IC 50 34 nM followed by 11q and 11u with IC 50 92 and 93 nM, respectively.
Citation
Abdel-Maksoud, M. S., Ammar, U. M., El-Gamal, M. I., Gamal El-Din, M. M., Mersal, K. I., Ali, E. M., Yoo, K. H., Lee, K.-T., & Oh, C.-H. (2019). Design, synthesis, and anticancer activity of imidazo[2,1-b]oxazole-based RAF kinase inhibitors. Bioorganic Chemistry, 93, Article 103349. https://doi.org/10.1016/j.bioorg.2019.103349
Journal Article Type | Article |
---|---|
Acceptance Date | Oct 5, 2019 |
Online Publication Date | Oct 10, 2019 |
Publication Date | 2019-12 |
Deposit Date | Dec 11, 2022 |
Journal | Bioorganic Chemistry |
Print ISSN | 0045-2068 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 93 |
Article Number | 103349 |
DOI | https://doi.org/10.1016/j.bioorg.2019.103349 |
Keywords | Anticancer, B-RAF inhibitors, Imidazo[2,1-b]oxazole, Kinase inhibitor, SAR |
Public URL | http://researchrepository.napier.ac.uk/Output/2982052 |
You might also like
Downloadable Citations
About Edinburgh Napier Research Repository
Administrator e-mail: repository@napier.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search